JP2016540729A - 酢酸グラチラマーへの応答を予測する遺伝子マーカー - Google Patents
酢酸グラチラマーへの応答を予測する遺伝子マーカー Download PDFInfo
- Publication number
- JP2016540729A JP2016540729A JP2016522037A JP2016522037A JP2016540729A JP 2016540729 A JP2016540729 A JP 2016540729A JP 2016522037 A JP2016522037 A JP 2016522037A JP 2016522037 A JP2016522037 A JP 2016522037A JP 2016540729 A JP2016540729 A JP 2016540729A
- Authority
- JP
- Japan
- Prior art keywords
- kgp
- snp
- genotype
- snps
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims abstract description 210
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims abstract description 180
- 229960003776 glatiramer acetate Drugs 0.000 title claims abstract description 180
- 230000004044 response Effects 0.000 title claims description 132
- 230000002068 genetic effect Effects 0.000 title description 64
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 135
- 238000000034 method Methods 0.000 claims abstract description 110
- 241000282414 Homo sapiens Species 0.000 claims abstract description 80
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 45
- 239000002773 nucleotide Substances 0.000 claims abstract description 44
- 102000054765 polymorphisms of proteins Human genes 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 239000003937 drug carrier Substances 0.000 claims abstract description 13
- 108700028369 Alleles Proteins 0.000 claims description 161
- 238000004458 analytical method Methods 0.000 claims description 123
- 108090000623 proteins and genes Proteins 0.000 claims description 89
- 108020004414 DNA Proteins 0.000 claims description 70
- 239000000523 sample Substances 0.000 claims description 62
- 102220482019 Neutral amino acid transporter A_V399I_mutation Human genes 0.000 claims description 61
- 238000003205 genotyping method Methods 0.000 claims description 40
- 238000003752 polymerase chain reaction Methods 0.000 claims description 40
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 26
- 238000012163 sequencing technique Methods 0.000 claims description 22
- 102220514784 Fatty acid-binding protein, liver_T94A_mutation Human genes 0.000 claims description 20
- 102210060528 rs1545223 Human genes 0.000 claims description 20
- 102220004786 rs241447 Human genes 0.000 claims description 20
- 102220211807 rs241449 Human genes 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 20
- 238000003776 cleavage reaction Methods 0.000 claims description 19
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 19
- 230000007017 scission Effects 0.000 claims description 19
- 102220211762 rs241442 Human genes 0.000 claims description 18
- 102000053602 DNA Human genes 0.000 claims description 17
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 17
- 102210016501 rs3885907 Human genes 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 14
- 238000004422 calculation algorithm Methods 0.000 claims description 13
- 206010061818 Disease progression Diseases 0.000 claims description 12
- 230000005750 disease progression Effects 0.000 claims description 12
- 102220536871 Junctional adhesion molecule-like_V193A_mutation Human genes 0.000 claims description 9
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 208000034189 Sclerosis Diseases 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 238000000018 DNA microarray Methods 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 101150049069 rpsM gene Proteins 0.000 claims 1
- 101150061587 rpsS gene Proteins 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 description 81
- 239000000902 placebo Substances 0.000 description 44
- 229940068196 placebo Drugs 0.000 description 44
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 29
- 229940038717 copaxone Drugs 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 238000011282 treatment Methods 0.000 description 24
- 230000003902 lesion Effects 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 16
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 238000007792 addition Methods 0.000 description 12
- 238000003491 array Methods 0.000 description 12
- 238000002595 magnetic resonance imaging Methods 0.000 description 11
- 238000000611 regression analysis Methods 0.000 description 11
- 238000012937 correction Methods 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 230000002974 pharmacogenomic effect Effects 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 102000054767 gene variant Human genes 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000000306 recurrent effect Effects 0.000 description 8
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000012098 association analyses Methods 0.000 description 6
- 238000013264 cohort analysis Methods 0.000 description 6
- 230000000750 progressive effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 5
- 108010005716 Interferon beta-1a Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 3
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 3
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 102000003996 Interferon-beta Human genes 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 102000047918 Myelin Basic Human genes 0.000 description 3
- 101710107068 Myelin basic protein Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 3
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 2
- 101150066375 35 gene Proteins 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 2
- 101000755875 Homo sapiens Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 2
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 2
- 101000578932 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Proteins 0.000 description 2
- 108010005714 Interferon beta-1b Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 102100028328 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Human genes 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102100035211 SEC14-like protein 3 Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229940003504 avonex Drugs 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940021459 betaseron Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 229940042385 glatiramer Drugs 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 229960005027 natalizumab Drugs 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000009251 neurologic dysfunction Effects 0.000 description 2
- 208000015015 neurological dysfunction Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 229940038850 rebif Drugs 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102000006941 Amino Acid Transport System X-AG Human genes 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102100035037 Calpastatin Human genes 0.000 description 1
- 101150084121 Cdca7 gene Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108091006151 Glutamate transporters Proteins 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108050009377 Glypican-5 Proteins 0.000 description 1
- 108020004202 Guanylate Kinase Proteins 0.000 description 1
- 102100036117 HLA class II histocompatibility antigen, DQ beta 2 chain Human genes 0.000 description 1
- 102210059845 HLA-DRB1*15:01 Human genes 0.000 description 1
- 101000930799 Homo sapiens HLA class II histocompatibility antigen, DQ beta 2 chain Proteins 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000634545 Homo sapiens Neuronal PAS domain-containing protein 3 Proteins 0.000 description 1
- 101000694802 Homo sapiens Receptor-type tyrosine-protein phosphatase T Proteins 0.000 description 1
- 101001092196 Homo sapiens Ret finger protein-like 3 Proteins 0.000 description 1
- 102100028084 Hyaluronan and proteoglycan link protein 1 Human genes 0.000 description 1
- 101710191341 Hyaluronan and proteoglycan link protein 1 Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 102100029051 Neuronal PAS domain-containing protein 3 Human genes 0.000 description 1
- 108010036505 Neutral Amino Acid Transport Systems Proteins 0.000 description 1
- 102000012106 Neutral Amino Acid Transport Systems Human genes 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102100028645 Receptor-type tyrosine-protein phosphatase T Human genes 0.000 description 1
- 102100035528 Ret finger protein-like 3 Human genes 0.000 description 1
- 108091006271 SLC5A4 Proteins 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100020883 Solute carrier family 5 member 4 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 101150042718 Uvrag gene Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 108010044208 calpastatin Proteins 0.000 description 1
- ZXJCOYBPXOBJMU-HSQGJUDPSA-N calpastatin peptide Ac 184-210 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(C)=O)[C@@H](C)O)C1=CC=C(O)C=C1 ZXJCOYBPXOBJMU-HSQGJUDPSA-N 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 102000006638 guanylate kinase Human genes 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000004461 rapid eye movement Effects 0.000 description 1
- 238000004370 retrospective diagnosis Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 101150103887 rpsJ gene Proteins 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893807P | 2013-10-21 | 2013-10-21 | |
| US61/893,807 | 2013-10-21 | ||
| US201462048127P | 2014-09-09 | 2014-09-09 | |
| US62/048,127 | 2014-09-09 | ||
| US201462048641P | 2014-09-10 | 2014-09-10 | |
| US62/048,641 | 2014-09-10 | ||
| PCT/US2014/061647 WO2015061367A1 (en) | 2013-10-21 | 2014-10-21 | Genetic markers predictive of response to glatiramer acetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016540729A true JP2016540729A (ja) | 2016-12-28 |
| JP2016540729A5 JP2016540729A5 (enExample) | 2017-11-30 |
Family
ID=52826364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522037A Withdrawn JP2016540729A (ja) | 2013-10-21 | 2014-10-21 | 酢酸グラチラマーへの応答を予測する遺伝子マーカー |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9702007B2 (enExample) |
| EP (1) | EP3060681A4 (enExample) |
| JP (1) | JP2016540729A (enExample) |
| KR (1) | KR20160098199A (enExample) |
| CN (1) | CN105658818A (enExample) |
| AU (1) | AU2014340247A1 (enExample) |
| CA (1) | CA2926724A1 (enExample) |
| EA (1) | EA201690759A1 (enExample) |
| IL (1) | IL244783A0 (enExample) |
| MX (1) | MX2016005003A (enExample) |
| TW (1) | TW201610166A (enExample) |
| UY (1) | UY35790A (enExample) |
| WO (1) | WO2015061367A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定 |
| EP2906719A4 (en) | 2012-10-10 | 2016-11-09 | Teva Pharma | PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HRP20250396T1 (hr) | 2016-08-31 | 2025-05-23 | Mapi Pharma Ltd. | Depo sustavi koji sadrže glatiramer acetat |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CA3103385A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
| CN111088368B (zh) * | 2019-12-30 | 2021-04-16 | 山西医科大学 | 一种血液mRNA检测试剂盒及检测方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| AU757413B2 (en) | 1998-09-25 | 2003-02-20 | Yeda Research And Development Co. Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| CA2355400A1 (en) | 1998-11-12 | 2000-05-18 | Yeda Research And Development Co., Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
| MXPA02008023A (es) | 2000-02-18 | 2005-06-30 | Yeda Res & Dev | Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar. |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| AU7528001A (en) | 2000-06-05 | 2001-12-17 | Teva Pharma | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| NZ569331A (en) | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| EP1603530A1 (en) | 2003-03-04 | 2005-12-14 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| CA2525771A1 (en) | 2003-05-14 | 2004-12-02 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| US20050064483A1 (en) | 2003-08-28 | 2005-03-24 | Baylor College Of Medicine | Gene expression profiling technology for treatment evaluation of multiple sclerosis |
| EA200600877A1 (ru) | 2003-10-31 | 2006-12-29 | Тева Фармасьютикал Индастриз, Лтд. | Наночастицы для доставки лекарств |
| AU2005218625A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| EP1761276B1 (en) | 2004-06-25 | 2013-07-24 | ID Biomedical Corporation of Quebec | Compositions and methods for treating neurological disorders |
| EP1796710A4 (en) | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
| PL1797109T3 (pl) | 2004-09-09 | 2016-11-30 | Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania | |
| ES2338138T3 (es) | 2004-09-09 | 2010-05-04 | Teva Pharmaceutical Industries Ltd | Proceso para la preparacion de mezclas de polipeptidos utilizando acido bromhidrico purificado. |
| EP1838326A4 (en) | 2005-02-02 | 2009-09-30 | Teva Pharma | PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS |
| CA2596664A1 (en) | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| EP1891233A4 (en) | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| EP2111105A4 (en) | 2007-11-28 | 2011-05-04 | METHOD FOR DELAYING THE BEGINNING OF A CLINICALLY DEFINED CLINIC SCLEROSIS | |
| HRP20170929T1 (hr) * | 2008-09-17 | 2017-09-22 | Chiasma Inc. | Farmaceutski pripravci i odgovarajući postupci za isporuku |
| US8835111B2 (en) * | 2009-03-12 | 2014-09-16 | Brainco Biopharma S.L. | Genotyping tool for improving the prognostic and clinical management of MS patients |
| NZ577731A (en) * | 2009-06-16 | 2010-08-27 | Innate Therapeutics Ltd | Compositions and methods for treatment of multiple sclerosis |
| ATE549013T1 (de) | 2009-07-15 | 2012-03-15 | Teva Pharma | Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| SI2949335T1 (sl) * | 2009-08-20 | 2017-05-31 | Yeda Research & Development Company, Ltd. | Nizkofrekventna terapija z glatiramer acetatom |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| EP2728646B1 (en) * | 2011-07-01 | 2016-05-18 | Zeon Corporation | Membrane poreuse pour batteries secondaires, procédé de sa fabrication et utilisation de celle-ci |
| TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定 |
| EP2906719A4 (en) | 2012-10-10 | 2016-11-09 | Teva Pharma | PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE |
| BR112015014095A2 (pt) | 2012-12-21 | 2017-07-11 | Teva Pharma | entrega transmucosal de acetato de glatirâmero |
| BR112015014092A2 (pt) | 2012-12-21 | 2017-07-11 | Teva Pharma | administração oral transmucosal de acetato de glatirâmer |
| WO2014107533A2 (en) | 2013-01-04 | 2014-07-10 | Teva Pharmaceutical Industries Ltd. | Characterizing a glatiramer acetate related drug product |
| EP2968559A4 (en) | 2013-03-12 | 2016-11-02 | Teva Pharma | RITUXIMAB INDUCTION THERAPY FOLLOWED BY GLATIRAMERACETATE THERAPY |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2014
- 2014-10-20 UY UY0001035790A patent/UY35790A/es not_active Application Discontinuation
- 2014-10-21 JP JP2016522037A patent/JP2016540729A/ja not_active Withdrawn
- 2014-10-21 AU AU2014340247A patent/AU2014340247A1/en not_active Abandoned
- 2014-10-21 WO PCT/US2014/061647 patent/WO2015061367A1/en not_active Ceased
- 2014-10-21 US US14/520,280 patent/US9702007B2/en active Active
- 2014-10-21 TW TW103136383A patent/TW201610166A/zh unknown
- 2014-10-21 EA EA201690759A patent/EA201690759A1/ru unknown
- 2014-10-21 CN CN201480058055.6A patent/CN105658818A/zh active Pending
- 2014-10-21 CA CA2926724A patent/CA2926724A1/en not_active Abandoned
- 2014-10-21 KR KR1020167013482A patent/KR20160098199A/ko not_active Withdrawn
- 2014-10-21 EP EP14855499.1A patent/EP3060681A4/en not_active Withdrawn
- 2014-10-21 MX MX2016005003A patent/MX2016005003A/es unknown
-
2016
- 2016-03-28 IL IL244783A patent/IL244783A0/en unknown
-
2017
- 2017-01-19 US US15/410,091 patent/US20180002753A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2926724A1 (en) | 2015-04-30 |
| EP3060681A4 (en) | 2017-06-07 |
| US20180002753A1 (en) | 2018-01-04 |
| IL244783A0 (en) | 2016-04-21 |
| US20150110733A1 (en) | 2015-04-23 |
| MX2016005003A (es) | 2016-08-03 |
| UY35790A (es) | 2015-05-29 |
| CN105658818A (zh) | 2016-06-08 |
| TW201610166A (zh) | 2016-03-16 |
| KR20160098199A (ko) | 2016-08-18 |
| EA201690759A1 (ru) | 2017-01-30 |
| US9702007B2 (en) | 2017-07-11 |
| WO2015061367A1 (en) | 2015-04-30 |
| AU2014340247A1 (en) | 2016-06-02 |
| EP3060681A1 (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540729A (ja) | 酢酸グラチラマーへの応答を予測する遺伝子マーカー | |
| US9499868B2 (en) | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate | |
| Kraft et al. | Sequence analysis of the serotonin transporter and associations with antidepressant response | |
| US20150278438A1 (en) | Genetic predictors of response to treatment with crhr1 antagonists | |
| JP6496003B2 (ja) | Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー | |
| KR20090019848A (ko) | 알쯔하이머 병의 진행에 대한 생체마커 | |
| JP6272860B2 (ja) | 軟骨障害の予後バイオマーカー | |
| CN103789408B (zh) | 高血压易感基因组的鉴定 | |
| EP3011048A1 (en) | Method for predicting a treatment response to a crhr1 antagonist and/or a v1b antagonist in a patient with depressive and/or anxiety symptoms | |
| EP3277836B1 (en) | Method of treatment using genetic predictors of a response to treatment with ssr-125543 | |
| WO2010111080A2 (en) | Optimized treatment of schizophrenia | |
| US20160312284A1 (en) | Select single nucleotide polymorphisms predictive of response to glatiramer acetate | |
| CA3174572A1 (en) | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | |
| US20120164640A1 (en) | Methods and compositions for correlating genetic markers with sudden cardiac death risk | |
| WO2012106404A2 (en) | Diagnosis and treatment of neurological disorders through vipr2 and vpac2r | |
| Class et al. | Patent application title: DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR GLATIRAMER ACETATE Inventors: Teva Pharmaceutical Industries, Ltd.(Petach-Tikva, IL) Amir Tchelet (Hod-Hasharon, IL) Fabio Macciardi (Irvine, CA, US) Joseph Levy (Kfar-Sava, IL) Assignees: Teva Pharmaceutical Industries Ltd. | |
| HK1225412A1 (en) | Genetic markers predictive of response to glatiramer acetate | |
| WO2011117267A9 (en) | Cladribine treatment of multiple sclerosis in patient groups defined by genotype | |
| EP2314714A1 (en) | Disease susceptibility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171023 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171023 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20171220 |